Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma - Episode 1

Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma

This publication reviews the role of Bruton tyrosine kinase inhibitors and PI3K inhibitors, particularly in the relapsed or refractory setting, for the treatment of marginal zone lymphoma, recapping key insights from a scientific interchange & workshop.